Human rights and healthcare: changing the culture

Godwin J. Lower-limb risk factors for falls in people with diabetes mellitus. Diabet Med 2010; 27: 162–8. 33. Klein R, Klein BE. Diabetic eye disease. Lancet 1997; 350: 197–204. 34. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc 1998; 46: 58–64. 35. Shan PF, Wu XP, Zhang H et al. Bone mineral density and its relationship with body mass index in postmenopausal women with type 2 diabetes mellitus in mainland China. J Bone Miner Metab 2009; 27: 190–7. 36. Yamaguchi T, Kanazawa I, Yamamoto M et al. Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. Bone 2009; 45: 174–9. 37. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 2009; 160: 265–73. 38. Diniz-Santos DR, Brandäo F, Adan L, Moreira A, Vicente EJ, Silva LR. Bone mineralization in young patients with type 1 diabetes mellitus and screening-identified evidence of celiac disease. Dig Dis Sci 2008; 53: 1240–5. 39. Dandona P, Dhindsa S, Chandel A, Chaudhuri A. Hypogonadotropic hypogonadism in men with type 2 diabetes. Postgrad Med 2009; 121: 45–51. 40. Yamagishi S, Nakamura K, Inoue H. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses 2005; 65: 1013–5. 41. Danielson KK, Elliott ME, LeCaire T, Binkley N, Palta M. Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos Int 2009; 20: 923–33. 42. Nagasaka S, Murakami T, Uchikawa T, Ishikawa SE, Saito T. Effect of glycemic control on calcium and phosphorus handling and parathyroid hormone level in patients with noninsulin-dependent diabetes mellitus. Endocr J 1995; 42: 377–83. 43. Pittas AG, Chung M, Trikalinos T et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med 2010; 152: 307–14. 44. Hyppönen E, Laara E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358: 1500–3. 45. Avenell A, Cook JA, MacLennan GS, McPherson GC. Vitamin D supplementation and type 2 diabetes: a substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing 2009; 38: 606–9. 46. Knekt P, Laaksonen M, Mattila C et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008; 19: 666–71. 47. Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J 2005; 98: 1024–7. 48. Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diab Care 2008; 31: 845–51. 49. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32–9. 50. National Institute for Health and Clinical Excellence. Type 2 Diabetes — Newer Agents (Partial Update of CG66). London: Royal College of Physicians, 2009. 51. Weatherall M. Prevention of falls and fall-related fractures in community-dwelling older adults: a meta-analysis of estimates of effectiveness based on recent guidelines. Intern Med J 2004; 34: 102–8.